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epiCaPture: A Urine DNA 
Methylation Test for Early Detection 
of Aggressive Prostate Cancer
INTRODUCTION
Prostate cancer (PCa) is the most common non-
cutaneous malignancy in men and the third lead-
ing cause of cancer-related deaths in men in the 
Western world. In 2012, there were an estimated 
1.1 million men diagnosed with this disease. 
With an aging population, spread of Western-
ized diet, and increasing use of prostate-specific 
antigen (PSA) testing, this figure is predicted to 
double by 2035.1
PCa demonstrates extreme clinical heterogene-
ity. Overall, 10-year survival rates are close to 
100%2; thus, there is much interest in strategies 
to reduce overtreatment of low/intermediate- 
risk tumors.3 However, more than 300,000 men 
die as a result of PCa each year. This stark fig-
ure, together with the knowledge that overtreat-
ment comes with the high price of prevalent 
life-changing side effects, illustrates the need for 
tools to selectively identify high-risk PCa (those 
tumors with a high propensity to metastasize) 
at an early stage, while the disease is potentially 
curable.
Research is ongoing into methods to address 
this need and better risk-stratify patients. Devel-
opments include algorithms around PSA iso-
forms (ie, the four-kallikrein and Prostate Health 
Purpose Liquid biopsies that noninvasively detect molecular correlates of aggressive 
prostate cancer (PCa) could be used to triage patients, reducing the burdens of unnec-
essary invasive prostate biopsy and enabling early detection of high-risk disease. DNA 
hypermethylation is among the earliest and most frequent aberrations in PCa. We in-
vestigated the accuracy of a six-gene DNA methylation panel (Epigenetic Cancer of the 
Prostate Test in Urine [epiCaPture]) at detecting PCa, high-grade (Gleason score greater 
than or equal to 8) and high-risk (D’Amico and Cancer of the Prostate Risk Assessment] 
PCa from urine.
Patients and Methods Prognostic utility of epiCaPture genes was first validated in two 
independent prostate tissue cohorts. epiCaPture was assessed in a multicenter prospec-
tive study of 463 men undergoing prostate biopsy. epiCaPture was performed by quan-
titative methylation-specific polymerase chain reaction in DNA isolated from prebiopsy 
urine sediments and evaluated by receiver operating characteristic and decision curves 
(clinical benefit). The epiCaPture score was developed and validated on a two thirds 
training set to one third test set.
Results Higher methylation of epiCaPture genes was significantly associated with 
increasing aggressiveness in PCa tissues. In urine, area under the receiver operating 
characteristic curve was 0.64, 0.86, and 0.83 for detecting PCa, high-grade PCa, and high-
risk PCa, respectively. Decision curves revealed a net benefit across relevant threshold 
probabilities. Independent analysis of two epiCaPture genes in the same clinical cohort 
provided analytical validation. Parallel epiCaPture analysis in urine and matched biopsy 
cores showed added value of a liquid biopsy.
Conclusion epiCaPture is a urine DNA methylation test for high-risk PCa. Its tumor 
specificity out-performs that of prostate-specific antigen (greater than 3 ng/mL). Used 
as an adjunct to prostate-specific antigen, epiCaPture could aid patient stratification to 
determine need for biopsy.
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Index tests),4 and multifactorial risk-calculator 
nomograms, such as the Prostate Cancer Pre-
vention Trial and European Randomized Study 
of Screening for Prostate Cancer.5 Urine in par-
ticular is an attractive noninvasive route, with 
the potential to reduce the number of patients 
subjected to prostate biopsy. Urinary analysis of 
molecular correlates of aggressive disease could 
be used to triage patients and identify those who 
actually require an invasive prostate biopsy to 
histologically diagnose and grade their disease.
In 2012, Movember launched four collaborative 
Global Action Plan (GAP) initiatives, focusing 
on PCa biomarkers in urine, plasma, serum, and 
exosomes. The aim of the GAP1 urine project 
was to develop multiparametric urine biomark-
ers to facilitate early detection of aggressive PCa. 
Underpinning this aim was the cooperative 
establishment of prebiopsy post–digital rectal 
examination (DRE) urine biorepositories at each 
institution, with a confederated database housing 
accompanying clinical, pathologic, and lifestyle 
data. The GAP1 urine project united investiga-
tors from seven different countries studying pro-
teomic, transcriptomic, and epigenetic analytes.
Herein, we present the results of one of two 
DNA methylation panels investigated in GAP1 
urine, adhering to the REMARK (Reporting 
Recommendations for Tumor Markers) guide-
lines on correct reporting of prognostic bio-
marker research.6 The Epigenetic Cancer of the 
Prostate Test in Urine (epiCaPture) is a multi-
biomarker panel that quantitatively measures 
DNA hypermethylation at the 5′-regulatory 
regions of six genes (GSTP1, SFRP2, IGFBP3, 
IGFBP7, APC, and PTGS2), all of which have 
previously been reported in PCa.7-10 Cumulative 
evidence supports promoter hypermethylation 
and concomitant gene silencing in PCa initia-
tion7,11 and as a strong prognostic indicator.12,13 
The purpose of this study was to determine the 
accuracy of epiCaPture for noninvasive detec-
tion of PCa and aggressive PCa, as defined by 
Gleason score (greater than or equal to 8) on 
biopsy, as well as two widely used risk-stratification 
systems, namely, D’Amico14 and Cancer of the 
Prostate Risk Assessment (CAPRA).15
PATIENTS AND METHODS
Patient Population
This institutional review board–approved, multi-
center prospective study enrolled men who were 
scheduled for transrectal ultrasound-guided 
(TRUS) biopsy because of an elevated and/or 
increasing PSA and/or a suspicious DRE. Six 
centers from the United States (Emory Health-
care, Atlanta, GA), Canada (University Health 
Network and Lunenfeld-Tanenbaum Research 
Institute, Sinai Health Systems, Toronto), and 
Europe (St James’s Hospital, Mater Misericor-
diae University Hospital, and Tallaght Hospital, 
all in Ireland; Norfolk and Norwich University 
Hospital, England), collected prebiopsy, post-
DRE urine (≤ 50 mL) between January 2012 
and October 2015. Exclusion criteria included 
previous diagnosis of PCa, active urinary tract 
infection, recent prostate biopsy or transurethral 
resection of the prostate (less than 6 wk), and 
confirmed presence of metastatic disease (by pel-
vic magnetic resonance imaging or bone scan). 
Histopathologic evaluation of TRUS biopsy 
cores was carried out at each site as per standard 
procedure by local consultant histopathologists. 
In total, urine samples were collected from 503 
men, with matched formalin-fixed paraffin- 
embedded TRUS biopsy cores acquired, where 
available (Fig 1). Signed informed consent was 
obtained from all patients. The demographic, 
clinical, and pathologic data for the whole 
cohort are listed in Table 1. In addition to this 
prebiopsy population, a retrospective analysis of 
the epiCaPture gene loci was performed on two 
independent cohorts of prostate tissues (Fig A2; 
Data Supplement).
Sample Collection, Processing, and 
epiCaPture Analysis
Urine samples were stored on ice and processed 
within 4 hours of collection, following a Movem-
ber GAP1 standard operating procedure. Details 
of nucleic acid isolation and quantification and 
epiCaPture analysis are provided in Appendix 
Table A1 and the Data Supplement.
Statistical Analysis
Statistical analyses were performed with R version 
3.4.1 and GraphPad Prism version 6. Two-tailed 
tests were used, and P < .05 was considered sig-
nificant. The ability of epiCaPture genes (or 
the combination thereof), when applied to 
urine, to predict cancer (v no cancer detected 
on biopsy), high-grade cancer (Gleason score 
greater than or equal to 8 v all else), and 
high-risk cancer (v all else) as classified by 
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D’Amico and CAPRA was assessed by logistic 
regression models, built in a two thirds train-
ing set (n = 319) and validated in a one third 
test set (n = 134). Discriminatory ability of the 
models was assessed via sensitivity, specificity, 
positive predictive value, and negative predictive 
value (NPV) using the Youden index. Diagnostic 
potential was quantified using the area under the 
receiver operating characteristic curve (AUC). 
Clinical utility was assessed by decision curve 
analysis (DCA).16
RESULTS
epiCaPture Genes Demonstrate Prognostic 
Utility in Prostate Tissues
Mindful that most potential biomarkers fail to 
translate to the clinic,17 we first set out to verify 
the prognostic utility of each epiCaPture constit-
uent gene by measuring its methylation in two 
independent cohorts of radical prostatectomy 
samples. There was strong evidence for differ-
ences in mean methylation β-values between 
four different groups (benign, low-risk, aggres-
sive, and metastatic PCa) in a small cohort of 
prostate tissues (subjected to epithelial cell 
enrichment) measured using the Infinium 
HumanMethylation450 BeadChip (Fig 2A). 
Post hoc analyses revealed significantly higher 
methylation of each gene in aggressive and/or 
metastatic lesions compared with benign tissue. 
Extracting freely available data from the same 
analytical platform for a larger The Cancer 
Genome Atlas cohort yielded similar results; 
each epiCaPture gene demonstrated signifi-
cantly higher levels of DNA methylation in 
clinically significant and high-risk tumors, rel-
ative to histologically benign tissue (Fig 2B). 
Although there was some evidence of methyl-
ation in low-risk disease, only G1 (GSTP1) was 
methylated at significantly higher levels than 
benign tissue in both cohorts.
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epiCaPture target validation in prostate tissue
(Infinium HumanMethylation450 BeadChip)
epiCaPture urine test development
(quantitative methylation-specific PCR)
Laser capture microdissected cohort
   Cancer
   Benign
(n = 31)
(n = 21)
(n = 10)
TCGA radical prostatectomy cohort
   Cancer
   Benign
(n = 178)
(n = 144)
(n = 34)
(n = 50)
(n = 21)
(n = 12)
(n = 17)
Excluded
   Confirmed metastases
   Failed quality control
   Cancelled or invalid biopsy
Movember GAP1 multicenter urine
biomarker cohort
(n = 503)
FFPE TRUS biopsy cores
(n = 15)
Post-DRE urine
(n = 453)
Independent analysis
in two laboratories G1, G5
(n = 236)
2/3 Training set
   Biopsy positive
   Biopsy negative
(n = 319)
(n = 172)
(n = 147)
1/3 Test set
   Biopsy positive
   Biopsy negative
(n = 134)
(n = 72)
(n = 62)
Fig 1. Flow diagram of 
specimens used in the study. 
DRE, digital rectal examina-
tion; epiCaPture, Epigenetic  
Cancer of the Prostate Test 
in Urine; FFPE, formalin- 
fixed paraffin-embedded; 
GAP, Global Action Plan; 
PCR, polymerase chain 
reaction; TCGA, The Cancer 
Genome Atlas; TRUS, 
transrectal ultrasound.
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epiCaPture Performance Characteristics  
in Urine
In total, epiCaPture was performed on 453 urine 
samples (Fig 3). Logistic regression models 
were developed using a 319-specimen training 
set (corresponding to 70% of the total cohort) 
and then evaluated for their ability to correctly 
predict cancer/high-grade cancer/high-risk can-
cer in the remaining test set. Analyzing all six 
genes together (epiCaPture score) consistently 
performed better than individual genes or com-
binations thereof. epiCaPture showed a compa-
rable ability to predict cancer on biopsy as PSA 
(AUC for both, 0.64; Fig 3A), with a superior 
tumor specificity (0.98 v 0.81), considering both 
as continuous variables (Appendix Table A2). 
The prognostic value of epiCaPture was next 
studied. AUCs for detecting high-grade, high-
risk D’Amico and CAPRA were 0.86, 0.83, and 
0.80, respectively (Figs 3B-3D), with sensitivi-
ties of 0.85, 0.70, and 0.67 and NPV for all three 
prognostic end points greater than 0.94 (Appen-
dix Table A2). Combining epiCaPture and PSA 
correctly predicted all high-grade cancers on 
biopsy (AUC, 0.95). Not forgetting the clinical 
significance of Gleason 7 disease, we also applied 
the revised five-grade grouping system,18 with 
a view to detecting group 3 (Gleason 4 and 3) 
and above. The combination of epiCaPture and 
PSA gave the best model (AUC, 0.82; sensitivity, 
0.73; specificity, 0.76; Appendix Fig A1; Appen-
dix Table A2).
We next evaluated the training set data to select 
an epiCaPture score cutoff that could best inform 
the decision on whether to perform a biopsy. 
Applying a threshold greater than 0.73 detected 
38% of all cancers in the test set. Increasing 
this cutoff to greater than 1.25 detected 85% of 
high-grade disease, with a tumor specificity of 
86% (Figs 3E-3H). Compared with the clini-
cally accepted PSA threshold of 3 ng/mL, this 
represents a 75% improvement in tumor spec-
ificity. Within the total study cohort, 245 men 
fell within the prognostically challenging PSA 4 
to 10 ng/mL bracket. Of these 245, 35 (14.29%) 
men had high-grade cancer. At the greater 
than 1.25 threshold, 14 of 35 (40%) of these 
men with high-grade disease tested positive for 
epiCaPture. Finally, DCA showed that at this 
threshold, epiCaPture demonstrated a net ben-
efit over PSA in the decision on whether to 
perform a biopsy, enabling a 15% reduction in 
prostate biopsies (Figs 3I and 3J).
epiCaPture Genes Show High 
Reproducibility by Independent Analysis
To examine the robustness of epiCaPture, a 
matched quantitative methylation specific PCR 
analysis of two of the panel (G1: GSTP1, and G5: 
APC) was carried out in two independent labora-
tories on 236 of the urine samples. Although the 
genes were the same, some differences existed in 
the target and control amplicon sequences and 
post-PCR analytical formulae (Data Supplement). 
Considering the sample set as a whole, irrespec-
tive of grade or other factors, both genes demon-
strated a moderate correlation in methylation 
values between the two laboratories (r = 0.55, r = 
0.56; P < .001; Fig 4A). However, the correlation 
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Table 1. Parameters of the Study Cohort
Parameter
Biopsy Negative 
(No.)
Biopsy Positive 
(No.) P
No. of patients (N 
= 453)
209 244
United States 19 15
Canada 24 58
England 101 115
Ireland 65 56
Age, years
Mean 64.29 66.96 < .001
Median 65 67 .0011
Range 40-83 47-85
PSA, ng/mL
Mean 7.43 12.31 < .001
Median 6.10 8.00 < .001
Range 0.01-63.80 0.47-87.70
Gleason score
6 84
7 113
≥ 8 47
D’Amico risk group
LR 63
IR 106
HR 75
CAPRA risk group
LR (0-2) 65
IR (3-5) 107
HR (> 5) 72
Abbreviations: CAPRA, Cancer of the Prostate Risk Assessment; HR, high risk; IR, intermediate 
risk; LR, low risk; PSA, prostate-specific antigen.
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Fig 2. Epigenetic Cancer of the Prostate Test in Urine (epiCaPture) gene validation in prostate tissue specimens. DNA methylation was mea-
sured using the Infinium HumanMethylation450 BeadChip (HM450k) in two independent cohorts of patients undergoing radical prostatectomy. 
(A) Laser capture microdissected enriched prostate epithelial cells from benign prostate tissue (procured from men undergoing radical cystopros-
tatectomy for bladder cancer, with no clinical or histologic evidence of prostate cancer [PCa]) and low-risk, aggressive, and metastatic PCa. (B) 
Data extracted from the TCGA repository for matched-benign prostate tissue and low-risk, significant, and high-risk PCa, all procured from men 
undergoing radical prostatectomy. A full description of the two cohorts is provided in the Data Supplement. Each data set was analyzed by one-way 
analysis of variance (ANOVA), followed by post hoc analyses using the Tukey-Kramer multiple comparisons test. Boxes indicate the 25th and 75th 
percentiles, the line represents the median, and the whiskers show the minimum and maximum value in each cohort of samples. Significance is 
indicated by *P < .05, **P < .01, *** P < .001, and **** P < .0001.
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Fig 3. Epigenetic Cancer of the Prostate Test in Urine (epiCaPture) performance at noninvasive detection of prostate cancer in urine. The per-
formance of epiCaPture compared with/in conjunction with prostate-specific antigen (PSA; treated as a continuous variable) in the test set (n = 134) 
for predicting each end point was assessed by receiver operating characteristic curves: (A) cancer (v no cancer detected on transrectal ultrasound bi-
opsy), (B) high-grade cancer (Gleason score greater than or equal to 8 v all else), (C) D’Amico high-risk cancer (v all else), and (D) CAPRA (Cancer 
of the Prostate Risk Assesment) high-risk cancer (v all else). The distribution of epiCaPture scores in the whole study population (n = 453), viewed 
by (E) biopsy outcome, (F) Gleason grade, (G) risk categorization by D’Amico risk-classification systems, and (H) risk categorization by CAPRA  
risk-classification system. The epiCaPture score was calculated for each sample by summing the normalized index of methylation (Data Supple-
ment) for G1 to G6. epiCaPture score distributions were analyzed by t test or one-way analysis of variance (ANOVA), followed by post hoc  
analyses using the Tukey-Kramer multiple comparisons test. For ease of interpretation, epiCaPture scores are plotted on a logarithmic axis, and  
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increased for both genes, when considering only 
the biopsy-positive samples (n = 122; r = 0.70, 
r = 0.66; P < .001; Fig 4B), the high-grade sam-
ples (r = 0.92, r = 0.88; P < .001; Fig 4C), or 
high-risk samples by applying either D’Amico 
(r = 0.88, r = 0.83; P < .001; Fig 4D) or CAPRA 
(r = 0.91, r = 0.85; P < .001; Fig 4E) risk strati-
fication. Furthermore, matched data were avail-
able for 18 of 30 high-risk/grade samples that 
were epiCaPture negative, of which 15 (83.33%) 
and 16 (88.89%) were also negative for G1 and 
G5, respectively, in the independent analysis.
Parallel epiCaPture Analysis in Urine and 
Matched Biopsy Cores Highlights Value of 
Liquid Biopsy
PCa is renowned for its multifocal nature. A 
concern for any liquid biopsy is therefore how 
well it captures molecular aberrations occurring 
within discrete tumor foci. Matched formalin- 
fixed paraffin-embedded biopsy cores were 
available for a proportion of patients, enabling 
parallel epiCaPture analysis on multiple tumor 
foci and urine from individual men (n = 15). G1 
to G6 methylation was higher in biopsy cores 
than in urine (Appendix Fig A2A), indicative of 
the higher tumor content in tissue over liquid 
biopsies. Similarly, individuals demonstrated 
higher epiCaPture scores in tissues than in urine 
(Appendix Fig A2B). The most interesting 
insights came from the matched analysis of urine 
with multiple biopsy cores, of which two notable 
cases are highlighted.
Patient SJH149 was diagnosed with a minute 
focus of Gleason score 6 adenocarcinoma. His 
urine epiCaPture score was strongly positive. 
A repeat biopsy revealed high-grade cancer in 
40% of cores on the right side (Fig 5A). epiCaP-
ture analysis of the original biopsy cores revealed 
DNA methylation, albeit at a magnitude lower 
than detected in urine. Notably, the epiCaPture 
fingerprint (ie, the relative contribution of each 
gene to the epiCaPture score) differed between 
tissue cores and urine. This finding could suggest 
that the source of the tumor DNA analyzed in 
urine could have been the high-grade tumor, 
which was not sampled on the original biopsy. 
In contrast, patient SJH189 was diagnosed with 
a high-percentage, high-grade (intermixed pat-
terns of grade 4 and 5) PCa on both sides of 
his prostate. His urine epiCaPture score was 
strongly positive, as were his tissue cores (Fig 5B). 
His epiCaPture fingerprint was comparable 
across urine and tissue cores, with a strong 
contribution from G1 to G4, smaller contribu-
tion from G5, and G6 negligible. So, despite 
pathologic heterogeneity within the gland, the 
three tumor areas seemed to be epigenetically 
homogeneous.
DISCUSSION
In this urine PCa biomarker study, we evalu-
ated the performance of epiCaPture, a six-gene 
DNA methylation panel, for noninvasive detec-
tion of PCa and more specifically high-grade or 
high-risk PCa in urine from patients referred 
for prostate biopsy on the basis of elevated 
PSA and/or abnormal DRE. Complying with 
REMARK guidelines, we describe a new DNA 
methylation-based urine test for early detection 
of aggressive PCa.
Many prostate tumors display a protracted dis-
ease trajectory, almost indolent in behavior.19 
The widespread use of the serum PSA test in 
many countries has significantly increased the 
incidence and thus overtreatment of these low-
risk cancers with little likelihood of clinical 
manifestation.20-23 An important first consider-
ation in developing epiCaPture was to therefore 
critically appraise the evidence for prognostic 
utility of each constituent gene. Using two inde-
pendent cohorts of prostate tissues, we showed 
that the DNA methylation of epiCaPture genes 
increases with aggressiveness. Conversely, how-
ever, it is estimated that approximately two thirds 
of men undergoing invasive prostate biopsy have 
no tumor diagnosed, because of the high false- 
positive rate of serum PSA.23,24 As such, millions 
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samples that were negative (epiCaPture score = 0) are not shown. Solid black line represents the mean of each group. Dashed lines indicate the 
epiCaPture score thresholds derived in the training set to maximize both sensitivity and specificity. Significance is indicated by *P < .05, **P < .01,  
***P < .001, and ****P < .0001. (I) Decision curve analysis demonstrated net clinical benefit of performing biopsy on patients in the test set on the  
basis of an epiCaPture score greater than 1.25 versus PSA greater than or equal to 3 ng/mL across a range of clinically relevant threshold proba-
bilities (the risk of cancer, such that a patient would choose to undergo biopsy by weighing the relative harms of false-positive and false-negative 
predictions). The horizontal gray line represents the decision curve for performing biopsy on no patients and the red line represents the decision 
curve for performing biopsy on all patients. (J) This translates to a net reduction in biopsies of approximately 15%, as compared with PSA, across a 
range of threshold probabilities. AUC, area under the receiver operating characteristic curve.
Fig 3. (Continued).
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Fig 4. Robustness of 
Epigenetic Cancer of the 
Prostate Test in Urine 
(epiCaPture) assays by in-
dependent verification. (A) 
Two of the six epiCaPture 
assays (G1: GSTP1 and G5: 
APC) were analyzed inde-
pendently in laboratories in 
Ireland (Perry) and Canada 
(Bapat) by quantitative 
methylation specific PCR in 
urine sediments from 236 
of 453 men in the study. 
Relevant subsets were then 
considered by applying the 
study end points: (B) men 
with biopsy-positive disease, 
(C) men with high-grade 
(Gleason score greater 
than or equal to 8) prostate 
cancer, and men with high-
risk prostate cancer defined 
by (D) D’Amico, and (E) 
CAPRA (Cancer of the 
Prostate Risk Assessment) 
classification. Data from 
the two laboratories are 
differentiated by the labels 
Perry and Bapat to indicate 
the principle investigator 
at each site. In each data 
set, the normalized index 
of methylation (NIM) and 
percent methylated ratio 
(PMR) represent the nor-
malized data value for each 
sample. Correlation was 
calculated using Spearman 
rank correlation.
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of unnecessary biopsies are performed world-
wide each year, at great cost to our health care 
systems and causing significant anxiety, trauma, 
and comorbidities for patients.25,26 PSA accuracy 
has been improved by the development of algo-
rithms incorporating different PSA isoforms, 
namely the four-kallikrein and Prostate Health 
Index tests, with AUC values in the region of 
0.7 (all PCa) and 0.71 to 0.79 (high-grade PCa, 
Gleason score greater than or equal to 7).4,27,28 
However, PSA is a single biomarker; used alone 
it does not address PCa heterogeneity or inform 
on disease biology.
The multifocal nature of PCa together with 
small sampling (less than 5%) of the gland by 
TRUS biopsy is problematic; approximately 
20% of tumors are upgraded on radical prosta-
tectomy because of sampling error.29 Although 
ascopubs.org/journal/po JCO™ Precision Oncology 9
Base
Apex
Apex
C
B
A
C
B
A
A
B
D
D
E
E
F
F
R
ig
h
t
Le
ft
Base
R
ig
h
t
Le
ft
Repeat biopsy (8 months later)
Re
la
tiv
e 
Co
nt
rib
ut
io
n
of
 E
ac
h 
Ge
ne
 (%
)
Sample Type
40
60
80
100
20
0
B C
Biopsy Core(s)
DEF Urine
G6
G5
G4
G3
G2
G1
G6
G5
G4
G3
G2
G1
Re
la
tiv
e 
Co
nt
rib
ut
io
n
of
 E
ac
h 
Ge
ne
 (%
)
Sample Type
Biopsy Core(s)
BA DE Urine
40
60
80
100
20
0e
pi
Ca
Pt
ur
e 
Sc
or
e
SJH189
150
100
50
0
25
ep
iC
aP
tu
re
 S
co
re 20
15
10
5
0
SJH149
Histologically benign
TissueGleason 6
Gleason 7
Gleason t 8
Urine
Fig 5. Parallel Epigenetic Cancer of the Prostate Test in Urine (epiCaPture) analysis in liquid and tissue biopsies. Prostate maps are for 
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epiCaPture score calculated for matched tissue cores and urine. (A) Low-risk prostate cancer SJH149 (62 years of age; prostate-specific antigen, 
3.08 ng/mL) demonstrated that urine as a liquid biopsy is a viable alternative to sampling bias inherent to tissue needle biopsies. Original biopsy: 
tumor occupying less than 1% total volume in one of two cores on the left-hand side. DNA was extracted from cores B, C, and D + E + F. Re-
peat biopsy: tumor was present in the medial, anterior, and posterior of the right-hand side of the gland. (B) High-risk prostate cancer SJH189 
(80 years of age; prostate-specific antigen, 6.63 ng/mL) demonstrated similar epiCaPture fingerprint across different tumor areas sampled on 
biopsy and in urine.
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sophisticated imaging technologies, such as 
magnetic resonance imaging, may improve the 
accuracy of prostate biopsy,30 their widespread 
application is hampered by high cost, access to 
specialist equipment and personnel, interob-
server subjectivity, and requirement for anesthe-
sia. Alternatively, transperineal biopsy enables a 
more complete sampling of the gland, including 
the anterior prostate, but also requires anesthe-
sia and is thus unsuitable as a population-based 
detection method for such a prevalent disease.
The dearth of blood-based prognostic biomark-
ers as a screening tool for aggressive PCa in con-
junction with limitations of the prostate biopsy 
in its various forms has led to excitement around 
urine biomarkers. Physical manipulation of the 
prostate by DRE, followed by a first-void urinal-
ysis, could provide a simple, holistic insight into 
molecular alterations occurring in the prostate 
gland. Indeed, many studies have demonstrated 
significant value in detecting and noninvasively 
monitoring several genitourinary malignancies 
through urine.31-34 Some other prognostic urine 
indicators of aggressive PCa have already been 
described. For example, the Mi Prostate Score 
(MiPS), which incorporates the prostate-specific 
TMPRSS2-ERG fusion and PCA3 transcripts in 
urine, in conjunction with serum PSA, delivers 
AUCs of 0.75 and 0.78 for detecting all PCa and 
high-grade PCa, respectively.35 However, the 
prognostic value of this combination has been 
questioned by others.36,37 Combining expres-
sion of three genes (HOXC6, TRD1, and DLX1) 
functionally implicated in PCa with serum PSA 
detected clinically significant disease (Gleason 
score greater than or equal to 7 on biopsy), with 
an AUC of 0.81.38
Epigenetic alterations represent a particularly 
attractive source of biomarkers: promoter hyper-
methylation of many regulatory genes occurs 
early during prostate cancer initiation, it is often 
prognostic, and assessment of DNA is a more 
robust analyte than RNA. Early studies demon-
strated detection of GSTP1 methylation in urine 
from patients with PCa, although sensitivity 
was poor (less than 30%).39 Follow-up work 
expanded the repertoire of markers (GSTP1, 
APC, and RARβ2), which improved sensitivity 
to approximately 60%.40 The epiCaPture panel 
represents five commonly perturbed pathways in 
PCa: intracellular detoxification, Wnt and IGF 
axes, cell cycle, and prostaglandin biosynthesis. 
Assessing its diagnostic performance in terms of 
ability to predict cancer (irrespective of grade) on 
biopsy, epiCaPture was equivalent to PSA, with 
AUCs of 0.64. However, the reality of clinical 
practice is that PSA is not used as a continuous 
variable, with a threshold applied to guide deci-
sions on whether to biopsy. Taking the widely 
used cut-off of 3 ng/mL, the performance of PSA 
decreased to AUC of 0.55, in line with previous 
reports. In contrast, applying an epiCaPture 
threshold (greater than 0.73; developed on 
training set) did not markedly alter its diagnostic 
performance (AUC, 0.68) and delivered a 79% 
improvement over the tumor specificity of PSA.
In an effort to address the prognostic utility of 
epiCaPture within the context of the clinically 
heterogeneous Gleason 7 disease, we applied 
the revised five-grade grouping system,18 in 
addition to two widely used risk-classification 
systems. It should be noted all men with aggres-
sive cancers in this study had an elevated PSA; 
however, its specificity was poor. The epiCaP-
ture performance characteristics represent a 
potential improvement on existing methods for 
patient stratification and for determining the 
need to perform biopsy, detecting 85% of high-
grade tumors, with an NPV of 98%. Further-
more, the overlap of GSTP1 and APC in the two 
GAP1 urine DNA methylation biomarker pan-
els revealed excellent correlation in detection 
of aggressive PCa, illustrating the robustness of 
these biomarkers. In the context of the diagnos-
tic gray zone, PSA 4 to 10 ng/mL, epiCaPture 
demonstrated potential for further classifying 
patients, positive in 40% of men with high-
grade PCa. Applying DCA with epiCaPture 
showed a net reduction of approximately 15% in 
prostate biopsies. Given the high prevalence of 
this disease, this has the potential to dramatically 
reduce the number of biopsies being performed. 
Although these data are promising, a large pro-
spective clinical trial is needed to assess whether 
epiCaPture offers a survival advantage.
A limitation of our study is that the cohort is 
young; analysis was only possible using biopsy as 
the end point. We cannot rule out the possibil-
ity that a proportion of our epiCaPture-positive 
urine samples in men with low-grade or benign 
tissues were indeed tumor cases missed on 
biopsy. Longer-term follow-up is thus needed 
to more accurately assess the false-positive rate 
of epiCaPture (calculated at 5% in this study, 
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but presumed lower because of sampling error 
of TRUS biopsy). Evidence actually shows that 
DNA methylation detected in histologically 
benign tissue (due to an epigenetic field effect 
from the cancer), can be used as a tool to rule out 
the possibility that the biopsy missed the tumor. 
For example, the Confirm MDx test, which mea-
sures DNA methylation at three genes (GSTP1, 
APC, and RASSF1) in histologically benign 
biopsy tissue cores, is used to guide the decision 
to repeat a biopsy.41
Conversely, 14 of 47 (29.79%) high-grade tumors 
were epiCaPture negative. Independent analy-
sis revealed concordant negativity in more than 
80% of these men, and lowering the epiCaPture 
threshold did alter this result; they were nega-
tive across all six markers. Possible explanations 
such as low tumor volume were excluded. We 
believe that the most likely reason is interoper-
ator differences in DRE; these high-risk/grade 
cancers were epiCaPture negative because they 
had insufficient/undetectable prostate cells pres-
ent in their urine. Future work will focus on 
incorporating expression of a prostate-specific 
marker (ie, KLK2 or KLK3) into epiCaPture, to 
enable confirmation of the presence of prostate 
cells in the urine, validating its suitability for 
epiCaPture analysis and ultimately improving the 
performance of the test. Future work will also 
investigate the intra-individual reproducibility of 
epiCaPture by repeated measures in men.
Finally, to the best of our knowledge, this is the 
first PCa biomarker study to perform a matched 
analysis of tissue and liquid biopsies. A more 
extensive project is now warranted to fully assess 
the effects of the multifocal nature of PCa on 
signatures derived from liquid biopsies.
epiCaPture could be used in conjunction with 
existing tools (ie, PSA and risk calculators) to 
help guide the decision to biopsy. On further 
validation and cost-benefit analysis, epiCaPture 
may have utility as a population-based stratifi-
cation tool to identify those men who require a 
biopsy, to alleviate patient harms and hospital 
burdens of over-performing biopsies on patients.
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Fig A1. (A) The perfor-
mance of epiCaPture com-
pared to and in conjunction 
with prostate-specific 
antigen (PSA; treated as a 
continuous variable) in the 
test set (n = 134) for predict-
ing ISUP group 3, 4 and 5 
PCa on biopsy was assessed 
by receiver operator char-
acteristic curves. (B) The 
distribution of epiCaPture 
scores in biopsy-negative (no  
cancer detected) v biopsy- 
positive patients, categorized 
by ISUP group, shows 
increasing methylation by  
group. Significance is 
indicated by ***P < .001 and 
****P < .0001. ANOVA, 
analysis of variance; AUC, 
area under the receiver 
operating curve.
Downloaded from ascopubs.org by 139.222.163.118 on January 16, 2019 from 139.222.163.118
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
ascopubs.org/journal/po JCO™ Precision Oncology 17
Biopsy positive (low risk/grade, n = 5)
0.001
0.01
0.1
DN
A 
M
et
hy
la
tio
n
1
10
100
G1 G2 G3
Tissue
Urine
G4 G5 G6 epiCaPture
Tissue
Urine
A
Tissue
-20
0
20
40
60
80
Sample Type
Biopsy positive (high risk/grade, n = 5)
Paired t test, P = .02
ep
iC
aP
tu
re
 S
co
re
ep
iC
aP
tu
re
 S
co
re
Urine
-50
0
50
100
150
Biopsy positive (intermediate risk/grade, n = 5)
Paired t test, ns
Tissue
Sample Type
Urine
Biopsy positive (low risk/grade, n = 5)
Paired t test, ns
ep
iC
aP
tu
re
 S
co
re
Tissue
-2
0
2
4
6
8
Sample Type
Urine
B
Biopsy positive (intermediate risk/grade, n = 5)
DN
A 
M
et
hy
la
tio
n
G1
1
10
100
1,000
G2 G3 G4 G5 G6 epiCaPture
Tissue
Urine
Biopsy positive (high risk/grade, n = 5)
G1
DN
A 
M
et
hy
la
tio
n
1
10
100
1000
G2 G3 G4 G5 G6 epiCaPture
Fig A2. Parallel epiCaPture analysis in urine and matched biopsy cores. epiCaPture was performed in urine and matched formalin-fixed  
paraffin embedded biopsy cores from randomly selected biopsy-positive (n = 15: low-risk [CAPRA and D’Amico, Gleason score 6; intermediate 
risk, Gleason score 7; and high risk, Gleason score ≥ 8]) patients. (A) Parallel analysis of epiCaPture genes (G1-G6) in biopsy tissue cores and 
urine. DNA methylation of each gene is indicated by the NIM (normalised index of methylation), and for the collective panel, by the epiCaPture 
score (NIM sum G1-G6). Each point represents a single sample (biopsy core or urine), with the mean for each group indicated by a horizontal line 
(yellow, urine; blue, tissue). For ease of interpretation, DNA methylation is plotted on a logarithmic axis, and samples with no methylation are not 
shown. (B) Paired T tests on matched biopsy cores and urine reveal higher epiCaPture scores in tissues than in urine. For each patient, a single  
tissue epiCaPture score was calculated using the average across all cores studied (1-5). The epiCaPture threshold for urine positivity (1.25) is indi-
cated by a gray line. ns, not significant.
Downloaded from ascopubs.org by 139.222.163.118 on January 16, 2019 from 139.222.163.118
Copyright © 2019 American Society of Clinical Oncology. All rights reserved.
18 ascopubs.org/journal/po JCO™ Precision Oncology
Table A1. Description of epiCaPture qMSP Primers and Probes
Gene
Oligonucleotide Sequence (5′-3′)
Forward Reverse Probe
GSTP1 (G1) gtt gcg tgg cga ttt cg cga act ccc gcc gac c cga cga ccg cta cac
SFRP2 (G2) agt ttt tcg gag ttg cgc g gct ctc ttc gct aaa tac gac tcg tgt agc gtt tcg ttc gc
IGFBP3 (G3) ttt ttt cga tat cgg ttc gtc g gat ctc ctt aac ccc gcc g aga ttt tat ttc gag agc gga
IGFBP7 (G4) aag cgg gcg tga gat cg cgc gct cct act aac gtc g tta tgg gtc ggt tac gtc g
APC (G5) tta tat gtc cgt tac gtg cgt tta tat gaa cca aaa cgc tcc cca t ccc gtc gaa aac ccg ccg att a
PTGS2 (G6) cgg aag cgt tcg ggt aaa g gaa ttc cac cgc ccc aaa cg ttt ccg cca aat atc ttt tct tct tcg ca
Abbreviations: epiCaPture, Epigenetic Cancer of the Prostate Test in Urine; qMSP, quantitative methylation specific PCR.
Table A2. epiCaPture Performance Characteristics in Test Set
 Measurement AUC Accuracy Sensitivity Specificity PPV NPV
Biopsy-positive (cancer) v  
biopsy-negative (no cancer)
epiCaPture score* 0.64 0.63 0.35 0.98 0.96 0.56
PSA 0.64 0.60 0.48 0.81 0.64 0.68
epiCaPture score > 0.73 0.68 0.63 0.38 0.94 0.87 0.56
PSA ≥ 3 ng/mL 0.55 0.57 0.93 0.16 0.56 0.67
High-grade (Gleason score ≥ 8) v  
all else
epiCaPture score* 0.86 0.91 0.85 0.94 0.61 0.98
PSA 0.92 0.92 1.00 0.80 0.35 1.00
epiCaPture score and PSA 0.95 0.92 1.00 0.86 0.43 1.00
epiCaPture score > 1.25 0.85 0.90 0.85 0.86 0.39 0.98
PSA ≥ 3 ng/mL 0.56 0.90 1.00 0.12 0.11 1.00
High-risk D’Amico v  
all else
epiCaPture score* 0.83 0.87 0.70 0.93 0.64 0.95
epiCaPture score > 1.60 0.79 0.85 0.70 0.89 0.52 0.94
High-risk CAPRA v  
all else
epiCaPture score* 0.80 0.90 0.67 0.96 0.78 0.94
epiCaPture score > 1.20 0.76 0.82 0.67 0.85 0.45 0.93
High-grade Gleason group ≥ 3 
(Gleason score ≥ 4 + 3) v all else
epiCaPture score* 0.73 0.85 0.58 0.93 0.65 0.90
PSA 0.79 0.84 0.77 0.73 0.41 0.93
epiCaPture score and PSA 0.82 0.87 0.73 0.76 0.42 0.92
epiCaPture score > 1.20 0.73 0.81 0.57 0.88 0.54 0.90
PSA ≥ 3 ng/mL 0.54 0.81 0.96 0.13 0.21 0.93
NOTE. Accuracy denotes how well the model predicts the outcome on average.
Abbreviations: AUC, area under the curve; epiCaPture, Epigenetic Cancer of the Prostate Test in Urine; NPV, negative predictive value; PPV, positive predictive value; 
PSA, prostate-specific antigen.
*epiCaPture score was calculated by summing the normalized index of methylation of G1 to G6.
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